AXNX - Axonics Modulation Technologies Inc Stock Price, Fair Value and News

$70.980.00 (0.00%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AXNX Price Action

Last 7 days

0.8%

Last 30 days

1.1%

Last 90 days

3.1%

Trailing 12 Months

24.5%

AXNX RSI Chart

AXNX Valuation

Market Cap

3.6B

Price/Earnings (Trailing)

-643.1

Price/Sales (Trailing)

8.4

EV/EBITDA

354.71

Price/Free Cashflow

675.18

AXNX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AXNX Fundamentals

AXNX Revenue

Revenue (TTM)

431.9M

Rev. Growth (Yr)

24.8%

Rev. Growth (Qtr)

1.42%

AXNX Earnings

Earnings (TTM)

-5.6M

Earnings Growth (Yr)

-100.53%

Earnings Growth (Qtr)

-100.3%

AXNX Profitability

EBT Margin

-0.70%

Return on Equity

-0.85%

Return on Assets

-0.73%

Free Cashflow Yield

0.15%

AXNX Investor Care

Shares Dilution (1Y)

0.88%

Diluted EPS (TTM)

-0.11

AXNX Alerts

Big fall in earnings (Y/Y)

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	387.1M	408.8M	431.9M	0
2023	295.9M	319.8M	342.6M	366.4M
2022	194.3M	217.4M	240.9M	273.7M
2021	119.6M	150.3M	161.9M	180.3M
2020	39.0M	52.8M	86.7M	111.5M
2019	2.0M	3.3M	4.4M	13.8M
2018	0	369.7K	538.3K	707.0K
2017	0	0	0	201.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Axonics Modulation Technologies Inc

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

CEO	Mr. Raymond W. Cohen
WEBSITE	axonics.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	610

Axonics Modulation Technologies Inc Frequently Asked Questions

What is the ticker symbol for Axonics Modulation Technologies Inc? What does AXNX stand for in stocks?

AXNX is the stock ticker symbol of Axonics Modulation Technologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Axonics Modulation Technologies Inc (AXNX)?

As of Fri Nov 15 2024, market cap of Axonics Modulation Technologies Inc is 3.63 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXNX stock?

You can check AXNX's fair value in chart for subscribers.

Is Axonics Modulation Technologies Inc a good stock to buy?

The fair value guage provides a quick view whether AXNX is over valued or under valued. Whether Axonics Modulation Technologies Inc is cheap or expensive depends on the assumptions which impact Axonics Modulation Technologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXNX.

What is Axonics Modulation Technologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 15 2024, AXNX's PE ratio (Price to Earnings) is -643.1 and Price to Sales (PS) ratio is 8.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXNX PE ratio will change depending on the future growth rate expectations of investors.